Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of beta-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sj grens syndrome and type I diabetes research[1][2][3][4][5].
Molecular Weight:
(145.698 kDa)
Purity:
99.00
CAS Number:
[2515463-86-0]
Target:
TNF Receptor
Application Notes:
Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
